Otuska Extends Collaboration With Gelanea On Schizophrenia Drug Research
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceutical and American firm Galenea agreed to extend joint research and development of novel therapies for schizophrenia and other central nervous system diseases. The two companies started the collaboration in January 2005 and the new agreement extended the period from five years to six years. According to the agreement, Otsuka will pay as much as $75 million in research fees to Galenea. Galenea targets the relationship between calcineurin and CNS and is developing drug candidates to treat schizophrenia. (Click here for more - Japanese language